Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3381-3385

  Thompson, R Houston ^a   Kuntz, Susan M ^b   Leibovich, Bradley C ^a   Dong, Haidong ^b   Lohse, Christine M ^a   Webster, W Scott ^a   Sengupta, Shomik ^a   Frank, Igor ^a   Parker, Alexander S ^c   Zincke, Horst ^a   Blute, Michael L ^a   Sebo, Thomas J ^a   Cheville, John C ^a   Kwon, Eugene D ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CHILD; CONTROLLED STUDY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTIGENS, CD; CARCINOMA, RENAL CELL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS;

EID: 33645736792     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4303     Document Type: Article

References (20)

1. Uzzo RG, Rayman P, Kolenko V, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999;5:1219-29.
2. Kudo D, Rayman P, Horton C, et al. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res 2003;63:1676-83.
3. Rayman P, Wesa AK, Richmond AL, et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 2004;10:6360-65.
4. Chen L. Co-inhibitory molecules of the B7-28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-47.
5. Dong H, Zhu G, Tamada K, Chen L. B7-1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-9.
6. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
7. Latchman YE, Liang SC, Wu Y, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A 2004;101:10691-6.
8. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003;170:1257-66.
9. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-100.
10. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-9.
11. Thompson RH, Gillett MD, Cheville J, et al. Costimulatory molecule B7-1 in primary and metastatic clear cell renal cell carcinoma. Cancer 2005;104:2084-91.
12. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-400.
13. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7.
14. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96.
15. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-7.
16. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003;63:7462-7.
17. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64:1140-5.
18. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.
19. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-57.
20. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.